BVF PARTNERS L P/IL Insider Trading Transactions
Get free email notifications about insider trading for BVF PARTNERS L P/IL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is in Capstone Therapeutics Corp. ($CAPS) and 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in CTI BIOPHARMA CORP ($CTIC) and 10% Owner in XOMA Corp ($XOMA) and Director in XOMA Corp ($XOMA) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in INFINITY PHARMACEUTICALS, INC. ($INFI) and in FIVE PRIME THERAPEUTICS, INC. ($FPRX) and 10% Owner in FIVE PRIME THERAPEUTICS, INC. ($FPRX) and in CYTOKINETICS INC ($CYTK) and 10% Owner in CYTOKINETICS INC ($CYTK) and 10% Owner in GLYCOMIMETICS INC ($GLYC) and 10% Owner in CONCERT PHARMACEUTICALS, INC. ($CNCE) and 10% Owner in Syndax Pharmaceuticals Inc ($SNDX) and in Eledon Pharmaceuticals, Inc. ($NVUS) and in ChemoCentryx, Inc. ($CCXI) and 10% Owner in ChemoCentryx, Inc. ($CCXI) and 10% Owner in IMMUNE DESIGN CORP. ($IMDZ) and 10% Owner in Calithera Biosciences, Inc. ($CALA) and 10% Owner in Principia Biopharma Inc. ($PRNB) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and 10% Owner in Xenon Pharmaceuticals Inc. ($XENE) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Merus N.V. ($MRUS) and in IDEAYA Biosciences, Inc. ($IDYA) and 10% Owner in IDEAYA Biosciences, Inc. ($IDYA) and Director in Rain Therapeutics Inc. ($RAIN) and Director in Olema Pharmaceuticals, Inc. ($OLMA) and Director in Kymera Therapeutics, Inc. ($KYMR).
Latest Insider Trading Transactions of BVF PARTNERS L P/IL
Sentiment: All, ALPN, ARQL, CALA, CAPS, CCXI, CNCE, CTIC, CYTK, ELDN, FPRX, GLYC, IDYA, IMDZ, INFI, KYMR, MRUS, OLMA, PIRS, PRNB, RAIN, SNDX, XENE, XOMA
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 504 | 1,940 | 348,827 | 348.3 K to 348.8 K (+0.14 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 2,913 | 11,214 | 1,996,638 | 2 M to 2 M (+0.15 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 3,416 | 13,150 | 2,461,782 | 2.5 M to 2.5 M (+0.14 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.89 | 1,456 | 5,667 | 348,323 | 346.9 K to 348.3 K (+0.42 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.89 | 8,236 | 32,055 | 1,993,725 | 2 M to 2 M (+0.41 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.89 | 10,389 | 40,435 | 2,458,366 | 2.4 M to 2.5 M (+0.42 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.90 | 240 | 935 | 346,867 | 346.6 K to 346.9 K (+0.07 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.90 | 1,133 | 4,415 | 1,985,489 | 2 M to 2 M (+0.06 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.90 | 1,027 | 4,002 | 2,447,977 | 2.4 M to 2.4 M (+0.04 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 2,155 | 8,075 | 346,627 | 344.5 K to 346.6 K (+0.63 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 12,899 | 48,336 | 1,984,356 | 2 M to 2 M (+0.65 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 15,728 | 58,938 | 2,446,950 | 2.4 M to 2.4 M (+0.65 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 1,629 | 6,100 | 344,472 | 342.8 K to 344.5 K (+0.48 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 57,723 | 216,155 | 1,971,457 | 1.9 M to 2 M (+3.02 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 76,036 | 284,732 | 2,431,222 | 2.4 M to 2.4 M (+3.23 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 3,200 | 11,986 | 2,355,186 | 2.4 M to 2.4 M (+0.14 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.68 | 4,689 | 17,270 | 342,843 | 338.2 K to 342.8 K (+1.39 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.68 | 24,716 | 91,029 | 1,913,734 | 1.9 M to 1.9 M (+1.31 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.68 | 31,007 | 114,199 | 2,351,986 | 2.3 M to 2.4 M (+1.34 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 24,425 | 91,594 | 338,154 | 313.7 K to 338.2 K (+7.79 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 14,242 | 53,382 | 313,729 | 299.5 K to 313.7 K (+4.76 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 138,609 | 519,784 | 1,889,018 | 1.8 M to 1.9 M (+7.92 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 80,821 | 302,933 | 1,750,409 | 1.7 M to 1.8 M (+4.84 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 168,640 | 632,400 | 2,320,979 | 2.2 M to 2.3 M (+7.84 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 98,333 | 368,572 | 2,152,339 | 2.1 M to 2.2 M (+4.79 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 991 | 3,704 | 299,487 | 298.5 K to 299.5 K (+0.33 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 7,314 | 27,336 | 1,669,588 | 1.7 M to 1.7 M (+0.44 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 7,695 | 28,760 | 2,054,006 | 2 M to 2.1 M (+0.38 %) |
Sep 10 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 4.50 | 1,128 | 5,075 | 314,139 | 315.3 K to 314.1 K (-0.36 %) |
Sep 10 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 4.50 | 25,720 | 115,725 | 2,233,074 | 2.3 M to 2.2 M (-1.14 %) |
Sep 10 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 4.50 | 23,152 | 104,170 | 2,385,055 | 2.4 M to 2.4 M (-0.96 %) |
Sep 09 2019 | GLYC | GLYCOMIMETICS INC | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.18 | 124,956 | 397,610 | 528,891 | 403.9 K to 528.9 K (+30.93 %) |
Sep 09 2019 | GLYC | GLYCOMIMETICS INC | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.18 | 689,834 | 2,195,052 | 2,955,440 | 2.3 M to 3 M (+30.45 %) |
Sep 09 2019 | GLYC | GLYCOMIMETICS INC | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.18 | 853,956 | 2,717,288 | 3,639,935 | 2.8 M to 3.6 M (+30.65 %) |
Jun 12 2019 | CNCE | CONCERT PHARMACEUT ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 10.70 | 29,450 | 315,230 | 169,589 | 199 K to 169.6 K (-14.80 %) |
Jun 12 2019 | CNCE | CONCERT PHARMACEUT ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 10.70 | 158,583 | 1,697,457 | 952,859 | 1.1 M to 952.9 K (-14.27 %) |
Jun 12 2019 | CNCE | CONCERT PHARMACEUT ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 10.70 | 198,256 | 2,122,112 | 1,178,904 | 1.4 M to 1.2 M (-14.40 %) |
May 14 2019 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.74 | 13,816 | 203,664 | 746,454 | 732.6 K to 746.5 K (+1.89 %) |
May 14 2019 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.36 | 3,797 | 54,526 | 732,638 | 728.8 K to 732.6 K (+0.52 %) |
May 14 2019 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.57 | 10,300 | 150,037 | 728,841 | 718.5 K to 728.8 K (+1.43 %) |
Feb 01 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 284 | 0 | 284 | |
Feb 01 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 2,143 | 0 | 2,143 | |
Feb 01 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 2,573 | 0 | 2,573 | |
Feb 01 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 284,000 | 0 | 141,346 | 425.3 K to 141.3 K (-66.77 %) |
Feb 01 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 2,143,000 | 0 | 772,324 | 2.9 M to 772.3 K (-73.51 %) |
Feb 01 2019 | PIRS | PIERIS PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 2,573,000 | 0 | 978,200 | 3.6 M to 978.2 K (-72.45 %) |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 372 | 0 | 597 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 372 | 0 | 597 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 311 | 0 | 656 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 311 | 0 | 656 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 225 | 0 | 225 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 225 | 0 | 225 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 13,000.00 | 225 | 2,925,000 | 0 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 13,000.00 | 225 | 2,925,000 | 0 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 345 | 0 | 345 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 0.00 | 345 | 0 | 345 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 13,000.00 | 345 | 4,485,000 | 0 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 13,000.00 | 345 | 4,485,000 | 0 | |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.19 | 25,000 | 354,793 | 718,541 | 693.5 K to 718.5 K (+3.60 %) |
Dec 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.19 | 25,000 | 354,793 | 718,541 | 693.5 K to 718.5 K (+3.60 %) |
Dec 17 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.20 | 120,539 | 144,587 | 6,631,136 | 6.5 M to 6.6 M (+1.85 %) |
Dec 17 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.20 | 54,461 | 65,326 | 8,485,575 | 8.4 M to 8.5 M (+0.65 %) |
Dec 13 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.41 | 24,253 | 349,525 | 693,541 | 669.3 K to 693.5 K (+3.62 %) |
Dec 13 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.75 | 2,810 | 41,448 | 669,288 | 666.5 K to 669.3 K (+0.42 %) |
Dec 13 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.50 | 9,400 | 136,270 | 666,478 | 657.1 K to 666.5 K (+1.43 %) |
Dec 10 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.54 | 18,081 | 262,972 | 657,078 | 639 K to 657.1 K (+2.83 %) |
Dec 10 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.77 | 32,015 | 472,778 | 638,997 | 607 K to 639 K (+5.27 %) |
Dec 10 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.80 | 10,927 | 161,698 | 606,982 | 596.1 K to 607 K (+1.83 %) |
Dec 04 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.99 | 4,171 | 62,515 | 596,055 | 591.9 K to 596.1 K (+0.70 %) |
Dec 04 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.90 | 806 | 12,009 | 591,884 | 591.1 K to 591.9 K (+0.14 %) |
Dec 04 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.85 | 4,823 | 71,615 | 591,078 | 586.3 K to 591.1 K (+0.82 %) |
Dec 04 2018 | IMDZ | IMMUNE DESIGN CORP ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.83 | 89,948 | 164,929 | 370,391 | 460.3 K to 370.4 K (-19.54 %) |
Dec 04 2018 | IMDZ | IMMUNE DESIGN CORP ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.83 | 382,017 | 700,466 | 1,942,764 | 2.3 M to 1.9 M (-16.43 %) |
Dec 04 2018 | IMDZ | IMMUNE DESIGN CORP ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.83 | 430,035 | 788,512 | 2,502,758 | 2.9 M to 2.5 M (-14.66 %) |
Nov 30 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.30 | 100,000 | 130,000 | 6,510,597 | 6.4 M to 6.5 M (+1.56 %) |
Nov 29 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.93 | 10,016 | 149,543 | 586,255 | 576.2 K to 586.3 K (+1.74 %) |
Nov 29 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.11 | 8,288 | 125,262 | 576,239 | 568 K to 576.2 K (+1.46 %) |
Nov 29 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.24 | 11,396 | 173,680 | 567,951 | 556.6 K to 568 K (+2.05 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 581 | 784 | 1,254,993 | 1.3 M to 1.3 M (+0.05 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 4,119 | 5,561 | 8,431,114 | 8.4 M to 8.4 M (+0.05 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 5,573 | 7,524 | 1,254,412 | 1.2 M to 1.3 M (+0.45 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 38,001 | 51,301 | 6,410,597 | 6.4 M to 6.4 M (+0.60 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 50,044 | 67,559 | 8,426,995 | 8.4 M to 8.4 M (+0.60 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.37 | 81,648 | 111,841 | 1,248,839 | 1.2 M to 1.2 M (+7.00 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.37 | 556,709 | 762,580 | 6,372,596 | 5.8 M to 6.4 M (+9.57 %) |
Nov 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.37 | 733,151 | 1,004,270 | 8,376,951 | 7.6 M to 8.4 M (+9.59 %) |
Nov 21 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.00 | 25,000 | 374,893 | 556,555 | 531.6 K to 556.6 K (+4.70 %) |
Nov 21 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.68 | 37,482 | 512,701 | 531,555 | 494.1 K to 531.6 K (+7.59 %) |
Nov 21 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 9,771 | 136,064 | 494,073 | 484.3 K to 494.1 K (+2.02 %) |
Nov 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.82 | 10,849 | 149,986 | 484,302 | 473.5 K to 484.3 K (+2.29 %) |
Nov 19 2018 | XOMA | XOMA Corp | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.31 | 21,141 | 281,361 | 473,453 | 452.3 K to 473.5 K (+4.67 %) |
Nov 15 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 39,074 | 52,750 | 5,815,887 | 5.8 M to 5.8 M (+0.68 %) |
Nov 15 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 52,400 | 70,740 | 7,643,800 | 7.6 M to 7.6 M (+0.69 %) |
Nov 15 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.34 | 92,960 | 124,566 | 5,776,813 | 5.7 M to 5.8 M (+1.64 %) |
Nov 15 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.34 | 117,290 | 157,169 | 7,591,400 | 7.5 M to 7.6 M (+1.57 %) |
Nov 15 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 562,754 | 759,718 | 5,683,853 | 5.1 M to 5.7 M (+10.99 %) |
Nov 15 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.35 | 41,454 | 55,963 | 7,474,110 | 7.4 M to 7.5 M (+0.56 %) |
Jun 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.65 | 36,825 | 60,761 | 1,167,191 | 1.1 M to 1.2 M (+3.26 %) |
Jun 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.65 | 158,151 | 260,949 | 5,121,099 | 5 M to 5.1 M (+3.19 %) |
Jun 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.65 | 230,555 | 380,416 | 7,432,656 | 7.2 M to 7.4 M (+3.20 %) |
Jun 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.65 | 179,893 | 296,823 | 1,130,366 | 950.5 K to 1.1 M (+18.93 %) |
Jun 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.65 | 1,419,907 | 2,342,847 | 4,962,948 | 3.5 M to 5 M (+40.08 %) |
Jun 21 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.65 | 1,916,760 | 3,162,654 | 7,202,101 | 5.3 M to 7.2 M (+36.27 %) |
Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 188,746 | 0 | 188,746 | |
Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 705,863 | 0 | 705,863 | |
Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 1,105,391 | 0 | 1,105,391 | |
Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 188,746 | 0 | 85,038 | 273.8 K to 85 K (-68.94 %) |
Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 705,863 | 0 | 318,021 | 1 M to 318 K (-68.94 %) |
Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 1,105,391 | 0 | 498,025 | 1.6 M to 498 K (-68.94 %) |
Jun 01 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 5.00 | 175,813 | 879,083 | 771,305 | 947.1 K to 771.3 K (-18.56 %) |
Jun 01 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 5.00 | 312,266 | 1,561,361 | 3,186,044 | 3.5 M to 3.2 M (-8.93 %) |
Jun 01 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 5.00 | 547,860 | 2,739,355 | 4,682,669 | 5.2 M to 4.7 M (-10.47 %) |
Apr 20 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.10 | 217,256 | 673,494 | 947,118 | 1.2 M to 947.1 K (-18.66 %) |
Apr 20 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.10 | 808,449 | 2,506,192 | 3,498,310 | 4.3 M to 3.5 M (-18.77 %) |
Apr 20 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.10 | 1,204,668 | 3,734,471 | 5,230,529 | 6.4 M to 5.2 M (-18.72 %) |
Apr 11 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 97,453 | 194,906 | 950,473 | 853 K to 950.5 K (+11.42 %) |
Apr 11 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 365,682 | 731,364 | 3,543,041 | 3.2 M to 3.5 M (+11.51 %) |
Apr 11 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.00 | 546,865 | 1,093,730 | 5,285,341 | 4.7 M to 5.3 M (+11.54 %) |
Apr 11 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.90 | 62,437 | 118,630 | 853,020 | 790.6 K to 853 K (+7.90 %) |
Apr 11 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.90 | 208,872 | 396,857 | 3,177,359 | 3 M to 3.2 M (+7.04 %) |
Apr 11 2018 | INFI | INFINITY PHARMACEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.90 | 228,691 | 434,513 | 4,738,476 | 4.5 M to 4.7 M (+5.07 %) |
Apr 06 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.90 | 214,336 | 621,574 | 1,164,374 | 1.4 M to 1.2 M (-15.55 %) |
Apr 06 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.90 | 817,611 | 2,371,072 | 4,306,759 | 5.1 M to 4.3 M (-15.96 %) |
Apr 06 2018 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.90 | 1,269,634 | 3,681,939 | 6,435,197 | 7.7 M to 6.4 M (-16.48 %) |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 238,000 | 0 | 238,000 | |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 861,000 | 0 | 861,000 | |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 1,338,000 | 0 | 1,338,000 | |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 238,000 | 0 | 59,464 | 297.5 K to 59.5 K (-80.01 %) |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 861,000 | 0 | 216,694 | 1.1 M to 216.7 K (-79.89 %) |
Mar 29 2018 | XENE | Xenon Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 1,338,000 | 0 | 336,468 | 1.7 M to 336.5 K (-79.91 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 2,280 | 0 | 2,280 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 2,280 | 0 | 2,280 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 1,024 | 0 | 1,024 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 1,024 | 0 | 1,024 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 3,640 | 0 | 3,640 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 3,640 | 0 | 3,640 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 5,631 | 0 | 5,631 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 5,631 | 0 | 5,631 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 49 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 49 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 48 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 48 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 197 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 197 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 281 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 281 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 699,225 | 2,097,675 | 1,295,582 | 596.4 K to 1.3 M (+117.25 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 699,225 | 2,097,675 | 1,295,582 | 596.4 K to 1.3 M (+117.25 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 483,708 | 1,451,124 | 483,708 | 0 to 483.7 K |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 483,708 | 1,451,124 | 483,708 | 0 to 483.7 K |